Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2016

View Archived Issues

Phase I safety and pharmacokinetic results for BHV-0223

Orphan drug designation granted for RE-024 in Europe for the treatment of PKAN

European orphan drug designation for EYS-606 in refractory noninfectious uveitis

Data presented for phase II RADIANCE study of ozanimod

FDA approves Pfizer's Xeljanz XR extended-release tablets

Initiation of phase II study of fostamatinib in autoimmune hemolytic anemia

Alkermes announces positive topline results for 2-month dosing option of Aristada

FDA grants orphan drug designation to ZYN-002 for Fragile X syndrome

Roche discloses BACE1 inhibitors

Narcan now available in U.S. for the treatment of opioid overdose

Redx Pharma patents antibacterial compounds

Pfizer patent reports JAK inhibitors

University of British Columbia introduces pyruvate kinase inhibitors

PI3K and mTOR inhibitors described in Shandong Huiruidi Biotechnology patent

Interim phase III analysis shows improved pain scores in ER patients treated with ARX-04

Seattle Genetics initiates phase I trial of SGN-CD19B

NephroGenex pauses Pyridorin clinical program, restructures

Novartis seeks Japanese approval of artemether/lumefantrine

Phase I safety and PK data presented for BMS-986120

Teva to begin strategic corporate identity program to build global brand

UCB terminates epratuzumab agreement with Immunomedics

Takeda's combination packs for H. pylori eradication approved in Japan

EMA grants orphan drug designation to TNT-009 for autoimmune hemolytic anemia

Peregrine stops phase III bavituximab study in NSCLC following interim analysis

FDA places pivotal study of CR-845 for postoperative pain on protocol clinical hold

OSE Pharma and Effimune to merge

Luminex to validate GenArraytion's Zika virus assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...